Phase I and Pharmacokinetic Study of Oral Paclitaxel
Mirte M. Malingré(Meander Medisch Centrum), Jan H.M. Schellens(Utrecht University), Olaf van Tellingen(Dutch Cancer Society), Hilde Rosing(The Netherlands Cancer Institute), Franciska J. Koopman(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jos H. Beijnen(The Netherlands Cancer Institute), Jetske M. Meerum Terwogt(Amsterdam Public Health), W.W. ten Bokkel Huinink, Ken Duchin(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Martha Swart(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jan A. Lieverst(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)
Cited by 100
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884